MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Teleflex Incorporated Book Value 2011-2025 | TFX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Teleflex Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.28 B | 4.44 B | 4.02 B | 3.75 B | 3.34 B | 2.98 B | 2.54 B | 2.43 B | 2.14 B | 2.01 B | 1.91 B | 1.92 B | 1.78 B | 1.98 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.44 B | 1.78 B | 2.82 B |
Quarterly Book Value Teleflex Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.82 B | 4.24 B | 4.1 B | 4.48 B | 4.56 B | 4.5 B | 4.31 B | 4.22 B | 4.11 B | 4.02 B | 3.9 B | - | 3.8 B | 3.75 B | 3.66 B | 3.47 B | 3.38 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 2.98 B | 2.98 B | 2.98 B | 2.98 B | 2.54 B | 2.54 B | 2.54 B | 2.54 B | 2.43 B | 2.43 B | 2.43 B | 2.43 B | 2.14 B | 2.14 B | 2.14 B | 2.14 B | 2.01 B | 2.01 B | 2.01 B | 2.01 B | 1.91 B | 1.91 B | 1.91 B | 1.91 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.78 B | 1.78 B | 1.78 B | 1.78 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.56 B | 1.78 B | 2.79 B |
Book Value of other stocks in the Medical instruments industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
349 M | $ 24.56 | 0.7 % | $ 1.13 B |  USA |
 |
Baxter International
BAX
|
7.02 B | $ 19.52 | 1.93 % | $ 9.96 B | USA |
 |
Becton, Dickinson and Company
BDX
|
55.3 B | $ 200.48 | -0.23 % | $ 57.7 B | USA |
 |
Luminex Corporation
LMNX
|
199 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
76.5 M | - | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
12.7 M | $ 4.68 | 0.21 % | $ 94.4 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
257 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
411 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
762 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
388 M | - | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
73.1 M | $ 0.71 | -4.45 % | $ 30.1 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
66.7 M | - | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
4.2 B | $ 148.28 | -0.1 % | $ 3.62 B | USA |
 |
iRhythm Technologies
IRTC
|
90.9 M | $ 170.21 | 0.82 % | $ 5.31 B | USA |
 |
Alcon
ALC
|
21.6 B | $ 79.15 | 0.43 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
461 M | $ 41.07 | -3.09 % | $ 1.93 B | USA |
 |
Atrion Corporation
ATRI
|
243 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
7.44 M | $ 4.85 | 2.11 % | $ 26.7 K | USA |
 |
Repro Med Systems
KRMD
|
20.4 M | $ 5.8 | 0.35 % | $ 264 M | USA |
 |
AngioDynamics
ANGO
|
183 M | $ 13.42 | 2.13 % | $ 548 M | USA |
 |
The Cooper Companies
COO
|
8.24 B | $ 81.36 | -0.88 % | $ 16.2 B | USA |
 |
LeMaitre Vascular
LMAT
|
337 M | $ 83.04 | -1.14 % | $ 1.86 B | USA |
 |
Glaukos Corporation
GKOS
|
462 M | $ 111.73 | 2.6 % | $ 5.41 B | USA |
 |
Masimo Corporation
MASI
|
1.05 B | $ 137.35 | -0.72 % | $ 7.32 B | USA |
 |
Haemonetics Corporation
HAE
|
2.45 B | $ 80.24 | -3.89 % | $ 4.04 B | USA |
 |
InfuSystem Holdings
INFU
|
48 M | $ 9.22 | -0.27 % | $ 190 M | USA |
 |
Merit Medical Systems
MMSI
|
1.38 B | $ 86.49 | -0.24 % | $ 5.04 B | USA |
 |
Isoray
ISR
|
291 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
16.5 B | $ 559.7 | 3.2 % | $ 199 B | USA |
 |
OraSure Technologies
OSUR
|
410 M | $ 2.49 | - | $ 185 M | USA |
 |
Microbot Medical
MBOT
|
4.5 M | $ 2.23 | -7.65 % | $ 22.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
5.83 M | $ 0.36 | -7.4 % | $ 28.7 M | USA |
 |
Nephros
NEPH
|
8.36 M | $ 4.98 | -0.8 % | $ 51.7 M | USA |
 |
NeuroMetrix
NURO
|
14.3 M | - | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
3.36 B | $ 251.67 | -0.27 % | $ 36.8 B | USA |
 |
Envista Holdings Corporation
NVST
|
5.35 B | $ 22.07 | 0.46 % | $ 3.8 B | USA |
 |
Pro-Dex
PDEX
|
36.6 M | $ 44.0 | 1.43 % | $ 145 M | USA |
 |
STAAR Surgical Company
STAA
|
397 M | $ 23.49 | -2.65 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
6.62 B | $ 253.98 | 0.82 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
21.9 M | $ 2.35 | -1.05 % | $ 190 M | USA |
 |
Pulse Biosciences
PLSE
|
44.4 M | $ 14.04 | -1.4 % | $ 674 M | USA |
 |
Predictive Oncology
POAI
|
-203 K | - | - | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
1.96 B | $ 160.09 | 1.72 % | $ 8.92 M | USA |
 |
Utah Medical Products
UTMD
|
128 M | $ 57.54 | -0.96 % | $ 209 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.94 B | $ 11.43 | -1.21 % | $ 2.32 B | USA |
 |
Retractable Technologies
RVP
|
87.2 M | $ 0.84 | 1.99 % | $ 25.1 M | USA |
 |
West Pharmaceutical Services
WST
|
2.68 B | $ 271.82 | 1.6 % | $ 19.8 B | USA |